Clinic Software
About
Founded in 2019, AltrixBio is based on research by Jeff Karp, PhD, and Ali Tavakkoli, MD, of Mass General Brigham and Harvard Medical School. Inspired by the rapid resolution of type 2 diabetes following bariatric surgery, they modified sucralfate—a therapy with over 40 years of clinical use—to replicate these metabolic benefits, creating AJN003, a proprietary, bio-engineered, once-daily oral therapy. AJN003 forms a temporary barrier in the stomach, duodenum, and jejunum, altering nutrient sensing to trigger a metabolic reset. Preclinical data show it improves insulin resistance and key metabolic hormones (GLP-1, GIP, ghrelin, leptin), driving improved glycemic control and weight loss. As a small molecule with no systemic exposure, AJN003 offers a novel, patent-protected approach to treating type 2 diabetes, obesity, and other metabolic diseases. The AltrixBio team comprises scientists, clinicians, and business leaders with deep scientific, operational, and commercial expertise.
Product
- Value proposition
- AJN003 is a novel, oral, non-systemic therapy aiming to reset metabolic regulation by coating stomach and proximal intestine to replicate distal nutrient sensing, with potential for treating type 2 diabetes and obesity and broader metabolic indications.
Founders
- Nancy Briefs — Co-Founder
- Ali Tavakkoli — Co-Founder
- Jeff Karp — Co-Founder
Products
Key features
Technologies
Target conditions
Investors
News
- AltrixBio Raises $5 Million Series A Financing and Appoints David Pass as CEO to Advance Lead Candidate into the Clinic · 2025-09-16T12:10:00.000Z
- Our Leaders - AltrixBio · 2026-02-19T18:14:07.000Z
- AltrixBio Raises $5M in Series A Funding · 2025-09-16T15:33:38.000Z
- AltrixBio Raises $5M Series A and Appoints David Pass as CEO | citybiz · 2025-09-16T14:56:39.000Z
- AltrixBio: $5 Million Series A Closed For Developing Cardiometabolic Disease Treatment · 2025-09-17T17:51:56.000Z
- News and Insights - AltrixBio · 2025-09-13T01:29:05.000Z
